Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma
Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma
复制标题
DOI：
10.1136/jclinpath-2020-207002
复制
发表时间：
2020-10
影响因子：
3.4
通讯作者：
Masashi Morimachi;K. Hirabayashi;Yumi Takanashi;Aya Kawanishi;T. Saika;Yumiko Ueyama;T. Nakagohri;N. Nakamura;Hidekazu Suzuki;T. Kagawa
中科院分区：
文献类型：
--
作者：
Masashi Morimachi;K. Hirabayashi;Yumi Takanashi;Aya Kawanishi;T. Saika;Yumiko Ueyama;T. Nakagohri;N. Nakamura;Hidekazu Suzuki;T. Kagawa
胰腺导管腺癌（Pancreatic ductal adenocarcinoma，PDAC）是最致命的恶性肿瘤之一.因此，需要新的标记物和治疗策略。P68/DEAD box protein 5（DDX 5）是DEAD box蛋白家族的一种ATP依赖性RNA解旋酶。它是几种癌症的预后标志物。在这项研究中，我们的目的是评估DDX 5在PDAC中的表达和临床意义。方法采用免疫组织化学方法检测230例PDAC组织芯片中DDX 5的表达。当超过50%的细胞被染色时，DDX 5表达被认为是高的，当少于50%的细胞被染色时，DDX 5表达被认为是低的。我们研究了DDX 5表达与临床病理参数（包括患者生存率）之间的关系。结果DDX 5在正常胰腺导管、胰腺腺泡细胞和PDAC细胞核中表达阳性，但表达强度和分布不同。胰岛细胞显示强而弥漫的DDX 5染色。DDX 5低表达148例（64.3%），高表达82例（35.7%）。DDX 5低表达与晚期pT因子（pT 2-pT 3：肿瘤大小>20 mm）、淋巴结受累、晚期肿瘤淋巴结转移（TNM）分期（IIB、III和IV期）和静脉受累显著相关。多因素分析显示DDX 5表达是PDAC的独立预后因素。结论DDX 5在PDAC的侵袭性和预后中起重要作用。
Aims Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies. Hence, there is a need for new markers and treatment strategies. P68/DEAD box protein 5 (DDX5) is an ATP-dependent RNA helicase of the DEAD box protein family. It is a prognostic marker for several cancers. In this study, we aimed to evaluate the expression and clinical relevance of DDX5 in PDAC. Methods DDX5 expression in tissue microarray blocks containing 230 PDAC samples was examined using immunohistochemical analysis. DDX5 expression was considered high when more than 50% of the cells were stained and low when less than 50% of the cells were stained. We investigated the association between DDX5 expression and clinicopathological parameters, including patient survival. Results The nuclei of normal pancreatic ducts, normal acinar cells and PDAC cells were stained positive for DDX5 although the intensity and distribution of DDX5 expression varied. Islet cells showed strong and diffuse staining of DDX5. DDX5 expression was low and high in 148 (64.3%) and 82 cases (35.7%), respectively. Low DDX5 expression was significantly associated with an advanced pT factor (pT2–pT3: tumour size,>20 mm), lymphatic involvement, advanced tumour-node-metastasis (TNM) stage (stages IIB, III, and IV), and venous involvement. In addition, the multivariate analysis revealed that DDX5 expression is an independent prognostic factor for PDAC. Conclusion These results suggest that DDX5 plays an important role in tumour invasiveness and PDAC prognosis.